Introduction {#S0001}
============

As the sixth most common malignancy and the third most leading cause of tumor-related death, hepatocellular carcinoma (HCC) accounts for more than 90% of all hepato-malignancies worldwide.[@CIT0001],[@CIT0002] Patients with HCC have poor prognosis, with just 12.1% surviving after 5 years.[@CIT0003] Therefore, HCC represents a major health challenge.[@CIT0004] The standard therapeutic strategies for patients with HCC without metastasis are surgical approaches. Hepatectomy is the main therapeutic method used for patients with HCC in the Asia-Pacific region, especially for patients in China, due to the shortage of donor organs.[@CIT0003] However, there is a high recurrence rate after hepatectomy, which impacts the survival of patients with HCC. The cumulative recurrence within a 5-year period ranges from 50% to 70%.[@CIT0005]

It is proposed that early recurrence (ER) and late recurrence (LR) can be distinguished by the 2-year postoperative time point following curative resection of HCC.[@CIT0006],[@CIT0007] ER is associated with the pathological factors of aggressive tumors, including large tumor size, microvascular invasion (MVI), high tumor staging, microsatellite lesions, and high levels of serum alpha-fetoprotein (AFP). ER has been attributed to intrahepatic occult metastases or the multicenter metastasis of primary tumors.[@CIT0006]--[@CIT0010] In contrast, LR is caused by the formation of "de novo" tumors in the context of hepatitis and cirrhosis.[@CIT0002],[@CIT0006],[@CIT0007],[@CIT0011] Various risk factors for HCC recurrence after hepatectomy have been reported, but the results are often conflicting. Thus, an efficient model to predict recurrence after curative hepatectomy is urgently needed to develop individualized follow-up, early intervention, and improvements to prognosis.

Existing models/scoring systems are considered to have good predictive function, but they have shortcomings.[@CIT0012]--[@CIT0040] First, there is no standardized way of distinguishing ER and LR after hepatectomy in terms of recurrence time, which ranges from 0.5 years to 5 years after surgery.[@CIT0014],[@CIT0015],[@CIT0020],[@CIT0029],[@CIT0035],[@CIT0036] In some cases, predictive analyses are performed using an indicator of disease-free survival (DFS).[@CIT0012],[@CIT0014],[@CIT0016]--[@CIT0019],[@CIT0021]--[@CIT0027],[@CIT0031]--[@CIT0034] Some investigators have suggested using the time to recurrence, rather than recurrence-free survival, as the endpoint to predict and evaluate ER after HCC resection.[@CIT0041] Second, these systems tend to only be used for specific populations, limiting interpretation or the detection of consistent patterns across groups. For example, some predictive systems have been used for patients with portal vein tumor thrombus (PVTT)[@CIT0012],[@CIT0023],[@CIT0025],[@CIT0026],[@CIT0029],[@CIT0031],[@CIT0032],[@CIT0035] and bile duct tumor thrombus (BDTT),[@CIT0031] for which curative hepatectomy is not suitable.[@CIT0042] Third, scoring systems emphasize the weight of all risk factors in tumor recurrence; however, objective assessments of liver status are not available when using the liver fibrosis/cirrhosis in Child-Turcotte-Pugh (CTP) scoring system[@CIT0012],[@CIT0014] or the Model for end-stage liver disease (MELD) scoring system.[@CIT0012],[@CIT0033] There is not even qualitative evaluation of liver fibrosis/cirrhosis.[@CIT0015],[@CIT0018],[@CIT0019],[@CIT0024],[@CIT0025],[@CIT0029],[@CIT0035]--[@CIT0037] Therefore, this study aimed to develop novel prognostic nomograms characterized by easily collected and objective clinical data for ER and LR after curative hepatectomy.

Materials and Methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

All 318 patients with HCC that underwent radical hepatectomy in Hunan Provincial People's Hospital (The First Hospital Affiliated with Hunan Normal University) from January 2012 to January 2018 were recruited. Inclusion and exclusion criteria of patients with HCC after curative hepatectomy were based on the published literature.[@CIT0042] Inclusion criteria were: (a) Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 to 1 in the absence of macroscopic hepatic vein tumor thrombus, macroscopic bile duct tumor thrombus, extrahepatic spread, and/or distant metastases; (b) patients with preoperative status child-pugh A or B or with child-pugh ≥ B that recovered from child-pugh C after short-term therapy; (c) exact pathological diagnosis of HCC; and (d) patients with completely resected HCC (R0). Exclusion criteria were: (a) patients with other cancers in combination to HCC; (b) patients with cardiovascular, pulmonary disease or liver cirrhosis; (c) incomplete clinicopathological reports and follow-up data; and (d) perioperative death or postoperative death within 90 days of hospitalization. Patient data were retrospectively extracted from the medical records, which included demographic information, preoperative laboratory data, surgical results, pathological data, postoperative complications, recurrence and survival information, and oncologic outcomes. These data points were gathered and presented in [Table 1](#T0001){ref-type="table"}. This study conformed to the Helsinki principle and was approved by the Ethics Committee of Hunan Provincial People's Hospital. Every participant gave written informed consent.Table 1Patient Characteristics and Univariate Analysis of Postoperative RecurrenceFactors (n)ER (n=140)LR (n=24)n (%) or Median (Range)HR(95% CI)P valuen (%) or Median (Range)HR(95% CI)P valueGender Male (277)124(44.8)121(7.6)1 Female (41)16(39.0)0.941(0.559,1.584)0.8193(7.3)0.923(0.270, 3.152)0.898Age (year)51.0(15--73)0.985(0.971,0.998)0.02955.0(29--75)1.010(0.967, 1.056)0.652 ≤40 (48)26(54.2)10.3053(6.3)10.469 40-60 (180)80(44.4)0.800(0.513, 1.246)0.32313(7.2)0.599(0.219, 1.634)0.316 ≥60 (90)34(37.8)0.748(0.500, 1.119)0.1588(8.9)0.689(0.267, 1.778)0.442Dis-course (mon)0.3(0.01--18.2)1.012(0.953, 1.075)0.6910.2(0.02--12.0)1.047(0.874,1.254)0.618Smoking None (207)93(44.9)10.70713(6.3)10.414 Sometimes (9)6(66.7)1.169(0.809, 1.689)0.4061(1.1)0.968(0.422, 2.221)0.939 Often (102)41(40.2)1.091(0.463, 2.572)0.84210(9.8)1.021(0.778, 1.340)0.879Drinking None (213)95(44.6)10.22012(5.6)10.630 Sometimes (47)24(51.1)1.519(0.946, 2.440)0.0844(8.5)1.030(0.419, 2.529)0.949 Often (58)21(36.2)1.469(0.817, 2.640)0.1998(13.8)1.745(0.511, 5.962)0.374Symptom Yes (165)85(51.5)111(6.7)1 No (153)55(35.9)0.774(0.551, 1.088)0.14013(8.5)0.614(0.268, 1.408)0.249Weight Loss \<5 kg (280)114(40.7)124(8.6)1 ≥5 kg (38)26(68.4)2.151(1.396, 3.314)0.0010(0)------With DM No (291)129(44.3)122(7.6)1 Yes (27)11(40.7)1.183(0.639, 2.191)0.5932(7.4)2.637(0.587, 3.844)0.206HV Type None (37)9(24.3)10.8780(0)------ HBV (270)123(45.6)1.048(0.226, 4.859)0.95223(8.5)10.834 HCV (9)6(66.7)0.830(0.205, 3.364)0.7941(1.1)1.242(0.164, 9.405)0.834 HBV+HCV (2)2(100)0.712(0.143, 3.538)0.6780(0)------ HV Detection (Year)10.0(0--40.0)0.982(0.968, 0.996)0.01020.0(0--37.0)1.001(0.968, 1.036)0.935Antiviral Therapy None (284)122(43.0)10.77822(7.7)10.083 Entecavir (26)12(46.2)0.759(0.240, 2.405)0.6401(3.8)0.818(0.538, 1.243)0.347 Lamivudine (5)3(60.0)0.993(0.275, 3.581)0.9911(20.0)0.471(0.062, 3.573)0.466 Interferon (3)3(100)0.982(0.197, 4.883)0.9820(0)------ Antivirus (year)0(0--6.0)0.600(0.135, 2.660)0.5020(0--6.0)0.040(0.001, 1.189)0.063HBsAg + (261)120(46.0)120(7.7)1 − (57)20(35.1)0.855(0.532, 1.374)0.5184(7.0)0.796(0.269, 2.351)0.680Spontaneous HBsAg Seroclearance No (284)129(45.4)121(7.4)1 Yes (34)11(32.4)0.891(0.481, 1.651)0.7133(8.8)0.811(0.239, 2.757)0.737DNA2270.0\
(0--4.470×10^7^)1.000(1.000, 1.000)0.2523310.0\
(0.0--1.6×10^8^)1.000(1.000, 1.000)0.128DNA \>5×10^2^ (182)86(47.3)116(8.8)1 \<5×10^2^ (136)54(39.7)0.963(0.685, 1.353)0.8278(5.9)0.825(0.346, 1.963)0.663HBsAb − (286)126(44.1)123(8.0)1 + (32)14(43.8)1.298(0.746, 2.256)0.3561(3.1)0.345(0.042, 2.810)0.320Anti-HCV − (306)132(43.1)122(7.2)1 + (12)8(66.7)1.351(0.662, 2.760)0.4082(16.7)1.233(0.283, 5.378)0.781HBeAg − (298)129(43.3)122(7.4)1 + (20)11(55.0)1.458(0.786, 2.704)0.2322(10.0)1.204(0.276, 5.243)0.805HBeAb + (219)98(44.7)118(8.2)1 − (99)42(42.4)0.991(0.690, 1.422)0.9606(6.1)0.989(0.381, 2.567)0.982HBcAb + (287)129(44.9)122(7.7)1 − (31)11(35.5)0.822(0.444, 1.522)0.5332(6.5)0.779(0.179, 3.401)0.740With PH None (259)114(44.0)10.82222(8.5)10.885 Mild (37)15(40.5)1.003(0.585, 1.720)0.9922(5.4)1.115(0.256, 4.858)0.885 Moderate (17)7(41.2)1.134(0.538, 2.391)0.7400(0)------ Severe (5)4(80.0)1.520(0.546, 4.234)0.4230(0)------With SR No (265)106(40.0)121(7.9)1 Yes (53)34(64.2)1.175(0.798, 1.730)0.4143(5.7)1.070(0.302, 3.791)0.917CTP A (307)132(43.0)124(7.8)1 B (11)8(72.7)1.028(0.502, 2.104)0.9400(0)------Tumor MD (cm) ≤5(153)47(30.7)10.00013(8.5)10.923 5--10(119)62(52.1)1.415(0.968, 2.070)0.07310(8.4)0.924(0.118, 7.232)0.940 ≥10(46)31(67.4)2.763(1.748, 4.367)0.0001(2.2)1.096(0.135, 8.877)0.931Tumor Number 1 (244)95(38.9)10.00118(7.38)10.121 2 (35)12(34.3)0.762(0.418, 1.391)0.3764(11.4)1.108(0.767, 1.599)0.586 3 (10)9(90)1.765(0.858, 3.630)0.1221(10)1.242(0.161, 7.552)0.835 ≥4 (29)24(82.8)2.329(1.409, 3.851)0.0011(3.4)2.078(0.228, 9.967)0.517Tumor Location Left hemihepatic (70)26(37.1)10.3156(8.6)1 Right hemihepatic (222)92(41.4)1.110(0.708, 1.741)0.64918(8.1)1.241(0.487, 3.161)0.651 Bilobar (26)22(84.6)1.017(0.232, 4.464)0.9820(0)------Tumor Capsular No (186)74(39.8)115(8.1)1 Yes (132)66(50.0)0.330(0.045, 2.409)0.2759(6.8)0.900(0.383, 2.110)0.808AJCC-TNM IA (27)7(25.9)10.0021(3.7)10.285 IB (155)51(32.9)0.762(0.345,1.682)0.50114(9.0)1.419(0.182, 3.087)0.738 II (75)35(46.7)0.909(0.543, 1.523)0.7187(9.3)0.844(0.101, 4.072)0.876 IIIA (29)19(65.5)1.751(1.027, 2.986)0.0402(6.9)4.263(0.358, 7.709)0.251 IIIB (31)27(87.1)1.976(1.259, 3.101)0.0030(0)------ IVB (1)1(100)0.980(0.136, 7.059)0.9840(0)------BCLC Stage 0 (19)3(15.8)10.0001(5.3)10.571 A (224)84(37.5)1.053(0.333, 3.333)0.93019(8.5)1.124(0.146, 3.637)0.910 B (50)31(62.0)1.538(0.783, 3.023)0.2124(8.0)2.025(0.222, 4.430)0.531 C (25)22(88.0)2.389(1.332, 4.284)0.0030(0)------HKLC Stage I (143)41(28.7)10.00112(8.4)10.819 IIA (3)1(33.3)1.243(0.807, 1.915)0.3240(0)------ IIB (129)63(48.8)1.100(0.652, 1.856)0.72110(7.8)1.200(0.512, 2.81300.675 IIIA (2)2(100)1.795(1.034, 3.115)0.0380(0)------ IIIB (39)31(79.5)2.383(1.475, 3.850)0.0002(5.1)1.539(0.337, 7.023)0.577 IVA (2)2(100)1.448(0.356, 5.887)0.6050(0)------BS (mmol/L) \>3.9 (298)130(43.6)124(8.1)1 \<3.9 (20)10(50.0)2.131(1.114, 4.076)0.0220(0)------ALT/AST0.9(0.02--2.4)0.726(0.471, 1.118)0.1461.0(0.5--2.4)1.966(0.666, 5.805)0.221APRI0.7(0.2--10.5)1.000(0.858, 1.164)0.9960.5(0.2--3.5)1.031(0.524, 2.027)0.930Fib-42.4(0.3--21.8)1.002(0.934, 1.074)0.9621.7 (0.9--7.5)1.023(0.764, 1.368)0.881ALP (U/L)116.0(39.0--493.0)1.002(1.000, 1.004)0.08094.0(54.0--186.0)1.009(0.988, 1.030)0.430PA (mg/L)169.0(64.0--346.0)0.996(0.993, 0.999)0.005234.5(107.0--367.3)1.003(0.995, 1.010)0.501γ-GGT (U/L)88.2(16.10--1316.1)1.001(1.000, 1.002)0.00545.0(13.7--135.1)1.017(0.997, 1.037)0.090GPR1.0(0.2--22.2)1.047(0.989, 1.108)0.1120.5(0.1--2.3)2.230(0.692, 7.190)0.1795ʹ-NT (U/L)15.7(0.8--144.0)1.011(1.003, 1.019)0.00910.2(3.0--43.1)1.004(0.966, 1.043)0.853ALB (g/L)39.4(26.4--50.3)0.961(0.924, 0.999)0.04441.3(35.0--48.2)1.022(0.904, 1.155)0.730GLB (g/L)25.4(14.2--41.3)1.005(0.971, 1.042)0.76123.5(17.8--35.7)1.006(0.924, 1.096)0.890AG1.6(0.79--2.98)0.828(0.532 1.290)0.4041.8(1.0--2.3)0.918(0.297, 2.836)0.882ALBI−2.6(−3.5--−1.1)1.503(1.071, 2.109)0.019−2.8(−3.4--−2.2)1.890(0.727, 4.913)0.192ALBI Grade 1 (157)68(43.3)10.06314(8.9)1 2 (160)71(44.4)0.501(0.069, 3.645)0.49510(6.3)0.529(0.204, 1.376)0.192 3 (1)1(100)0.757(0.105, 5.488)0.7830(0)------TBIL (mmol/L)15.2(5.6--104.4)1.004(0.991, 1.017)0.56814.5(5.9--22.4)1.130(0.987, 1.295)0.077 ≤34.1 (308)135(43.8)124(7.8)1 \>34.1 (10)5(50.0)1.033(0.422, 2.527)0.9430(0)------DBIL (mmol/L)5.5(2.3--55.0)1.003(0.976, 1.031)0.8395.1(1.9--8.0)1.245(0.922, 1.683)0.153WBC (×10^9^)5.6(1.6--20.3)0.987(0.929, 1.049)0.6736.6(3.5--15.3)1.109(0.866, 1.419)0.412NLR2.6(0.7--16.0)1.007(0.950, 1.067)0.8172.4(1.0--18.9)1.195(1.015, 1.406)0.032MLR0.3(0.04--2.0)2.856(1.259, 6.478)0.0120.3(0.2--0.6)1.134(0.260, 4.947)0.867PLR117.1(41.5--440.5)1.003(1.000, 1.005)0.01995.1(48.4--165.2)1.001(0.990, 1.013)0.803AFP (μg/L)125.2(0.2--101,021.0)2.260(1.273, 4.013)0.00577.7(0.5--18,127.3)2.181(0.836, 5.693)0.111 0--20 (124)48(38.7)10.34111(8.9)10.379 20--400 (98)41(41.8)1.189(0.783, 1.804)0.4177(7.1)0.908(0.321, 2.568)0.856 \>400 (96)51(53.1)1.231(0.872, 1.739)0.2386(6.3)1.855(0.586, 5.869)0.293Operative Time (hr) ≤4 (181)64(35.4)118(9.9)1 \>4 (137)76(55.5)1.598(1.145, 2.231)0.0066(4.4)1.510(0.587, 3.885)0.393Surgical Approach Open (182)97(53.3)121(11.5)1 Laparoscopy (136)43(31.6)1.136(0.908, 1.423)0.2653(2.2)1.900(0.927, 3.896)0.080Type of Hepatectomy Nonanatomic (166)57(34.3)119(11.4)1 Anatomic (152)83(54.6)0.581(0.414, 0.816)0.0025(3.3)2.403(0.800, 7.220)0.118Extent of Hepatectomy Wedge (138)53(38.4)10.12417(12.3)10.434 1 segment (35)11(31.4)1.488(0.776, 2.855)0.2321(2.9)0.386(0.109, 1.367)0.140 2 segment (73)26(35.6)1.338(0.837, 2.140)0.2244(5.5)0.930(0.120, 2.181)0.944 3 segment (30)23(76.7)1.739(1.062, 2.848)0.0281(3.3)2.366(0.289, 3.377)0.422 ≥4 segment (42)27(64.3)1.827(1.141, 2.926)0.0121(2.4)2.763(0.332, 4.978)0.347 Intraoperative vascular occlusion Pringle maneuver (191)73(38.2)10.27117(8.9)1 Hemi-hepatic occlusion (7)4(57.1)0.615(0.512, 1.009)0.6300(0)------ Pringle maneuver + hemi-hepatic occlusion (120)63(52.5)0.719(0.246, 1.867)0.4527(5.8)0.892(0.573, 1.389)0.614 Vascular occlusion time (min)49.5(10.0--110.0)1.011(1.003, 1.019)0.00732.5(15.0--65.0)1.011(0.979, 1.044)0.496 Estimated blood loss (mL)150.0(5--2500)1.000(0.999, 1.000)0.667100.0(30.0--1000.0)1.001(1.000, 1.003)0.100 Intraoperative RBC transfusion (U)0(0--6)0.916(0.786, 1.069)0.2660(0--7)1.302(0.992, 1.709)0.057 Intraoperative Plasma transfusion (mL)0(0--800)1.000(0.998, 1.001)0.5730(0--400)1.004(0.999, 1.008)0.086 Resectional margin distance ≤1 cm (114)46(40.4)10.5977(6.1)1 1--2 cm (79)37(46.8)1.017(0.689, 1.502)0.9338(10.1)0.256(0.081, 0.808)0.020 ≥2 cm (125)57(45.6)0.831(0.539, 1.283)0.4049(7.2)0.497(0.175, 1.412)0.189 Histological subtype Trabecular (259)116(44.8)10.38024(9.3)1 Pseudoductular(26)12(46.2)0.865(0.120, 4.632)0.8850(0)------ Solid lesion (29)11(37.9)1.354(0.174, 6.225)0.7720(0)------ Fiber hardening (4)1(25.0)2.301(0.120, 7.166)0.4360(0)------Edmondson--Steiner Grade I (14)4(28.6)10.1862(14.3)10.062 II (144)56(38.9)1.145(0.161, 2.132)0.89216(11.1)1.179(0.166, 2.551)0.740 III (151)75(49.7)1.573(0.384, 3.447)0.5296(4.0)1.443(0.960, 2.984)0.153 IV (9)5(55.6)2.292(0.562, 3.344)0.2470(0)------METAVIR Inflammation Activity Grade A0 (38)15(39.5)10.1082(5.3)10.238 A1 (154)59(38.3)1.497(0.727, 3.084)0.27411(7.1)0.431(0.124, 1.499)0.186 A2 (94)50(53.2)1.001(0.583, 1.717)0.9987(7.4)0.443(0.119, 1.655)0.226 A3 (32)17(53.1)1.592(0.917, 2.762)0.0984(12.5)1.996(0.343, 2.611)0.442METAVIR Fibrosis Grade F0 (12)2(16.7)10.0111(8.3)10.566 F1 (33)13(39.4)1.078(0.194, 2.031)0.4371(3.0)1.032(0.103, 1.369)0.979 F2 (130)52(40.0)2.112(0.459, 3.678)0.69316(12.3)2.541(0.200, 2.862)0.678 F3 (61)32(52.5)3.245(1.047, 4.473)0.0133(4.9)3.567(0.339, 5.457)0.292 F4 (82)41(50.0)4.163(0.603, 5.527)0.8623(3.7)3.960(0.236, 6.516)0.330MVI M0 (208)72(34.6)10.00024(11.5)1 M1 (70)36(51.4)2.130(1.415, 3.206)0.0000(0)------ M2 (40)32(80.0)2.218(1.479, 3.328)0.0000(0)------HepParl + (279)116(41.6)120(7.2)1 (39)24(61.5)0.960(0.602, 1.529)0.8624(10.3)0.604(0.174, 2.102)0.429CD34 + (307)133(43.3)124(100)1 − (11)7(63.6)0.726(0.101, 5.221)0.7500(0)------P53 − (167)61(36.5)10.00814(8.4)10.277 Suspicious (16)6(37.5)2.152(0.667, 6.946)0.2007(43.8)0.333(0.041, 2.684)0.302 + (73)33(45.2)0.632(0.303, 1.319)0.2220(0)------ ++ (37)22(59.5)1.886(0.975, 3.650)0.0590(0)------ +++ (25)18(72.0)1.189(1.038, 1.363)0.0133(12.0)1.723(0.670, 4.433)0.259Ki 67 (%)25.0(0--75)1.015(1.005, 1.024)0.00215.0(0--50)1.026(0.989, 1.065)0.175Glypican-3 +(261)117(44.8)119(7.3)1 − (57)23(40.4)0.206(0.027, 1.576)0.1285(8.8)0.201(0.056, 0.726)0.014Postoperative CC None (280)119(42.5)10.47122(7.9)1 I (12)8(66.7)0.595(0.214, 1.650)0.3180(0)------ II (1)1(100)0.750(0.102, 5.513)0.7770(0)------ IIIa (18)7(38.9)1.310(0.464, 3.699)0.6102(11.1)1.101(0.674, 1.799)0.701 IIIb (7)5(71.4)1.726(0.839, 3.551)0.1380(0)--------Postoperative AT None (259)102(39.4)10.80520(7.7)10.633 TACE (53)33(62.3)0.880(0.216, 3.585)0.8594(7.5)0.766(0.256, 2.293)0.633 Targeted (4)3(75.0)1.058(0.253, 4.431)0.9380(0)------ Radiotherapy (2)2(100)1.135(0.189, 6.834)0.8900(0)------Postoperative Anti-HBV Yes (208)98(47.1)115(7.2)1 No (110)42(38.2)1.196(0.833, 1.717)0.3329(8.2)1.264(0.547, 2.920)0.583[^1]

Preoperative Examination {#S0002-S2002}
------------------------

Preoperative examinations were performed, including routine blood test, biochemistry test, serum alpha-fetoprotein (AFP) level, abdominal ultrasound, computed tomography (CT) and/or magnetic resonance imaging (MRI). Diagnosis criteria were based on the published literature.[@CIT0043] HCC was confirmed by (a) typical imaging characteristics of HCC being detected by at least two types of diagnostic equipment and at least two radiologists; (b) imaging examination combined with serum AFP \> 400 μg/L, and/or (c) indisputable cytological and histological evidence.

Indicators of Fibrosis/Cirrhosis {#S0002-S2003}
--------------------------------

The indicators of liver fibrosis/cirrhosis included (a) Aspartate aminotransferase-to platelet ratio (APRI):[@CIT0044] APRI=\[(AST(IU/L)/ULN of AST) ×100\]/(platelet count×10^9^/L). (b) Fibrosis index based on four factors (FIB-4):[@CIT0045] Fib-4=\[age (years)×AST (IU/L)\]/\[platelet count (10^9^/L)×(ALT (IU/L)^1/2^)\]. (c) Albumin-bilirubin (ALBI):[@CIT0046] ALBI= −0.085×(albumin (g/L))+(log10 bilirubin (mmol/L)×0.66), and ALBI classification: grade 1, ALBI\<−2.60; grade 2 (between −2.60\<ALBI and −1.39); grade 3, ALBI (above −1.39). (d) Gamma-glutamyl transpeptidase (GGT)-to platelet ratio (GPR):[@CIT0047] GPR = \[(GGT (IU/L)/ULN of GGT) ×100\]/\[platelet count (10^9^/L)\]. (e) Portal hypertension (PH), which is diagnosed by reference criteria according to the published literature:[@CIT0043] (1) esophageal and gastric varices are is detected by endoscopic examination, or (2) CT and (or) MRI examination show the enlargement of the spleen and laboratory examination shows platelet (PLT)\<100X10^9^/L. The degree of esophageal and gastric varices was determined by examination of imaging and/or endoscopy. The degree of PH was classified as: none, mild (slight esophagogastric varices), moderate (obvious esophagogastric varices without "red wale" signs), and severe (obvious esophagogastric varices with "red wale" signs). (f) The METAVIR score[@CIT0048] was used to assess the status of the non-tumor parts of the liver. (1) Liver tissue fibrosis was graded as F0: no fibrosis; F1: portal area fibrosis extends to the portal vein area, but no fibrous interval forms; F2: portal area fibrosis extends to most portal vein areas, with a few fiber intervals forming; F3: most fibrous spaces are formed, but without hardened nodules; and F4: cirrhosis. (2) Liver tissue inflammation activity: A0: no activity; A1: mild activity; A2: moderate activity; and A3: severe activity.

Tumor Characteristics, Staging, and Pathology {#S0002-S2004}
---------------------------------------------

Tumor size was determined from the maximum tumor diameter (measuring unit: centimeters) of the specimen during pathological examination. The number of tumor tissues was grouped as 1, 2, 3, and ≥4 (containing satellite nodules). Tumor encapsulation was assessed as the presence of intact capsules or absence of capsules. American Joint Committee on Cancer (AJCC) 8th edition TNM staging system,[@CIT0049] Barcelona Clinic Liver Cancer (BCLC) system,[@CIT0050] and Hong Kong Liver Cancer (HKLC) classification system[@CIT0051] were adopted to delineate tumor staging. Postoperative pathology was confirmed by at least two pathologists. Tumor differentiation was graded by the Edmondson-Steiner system.[@CIT0052] A tumor satellite, whether it was detected macroscopically or microscopically, was defined as a lesion that was separated from the primary tumor, and had a tumor diameter and distance from the main tumor of no more than 2 cm. Microvascular invasion (MVI) was diagnosed as the presence of tumor emboli in a vascular space lined by endothelial cells under a microscope, based on "the evidence-based practice guidelines for standardized pathological diagnosis of primary liver cancer in China: 2015 update".[@CIT0042] MVI was classified as M0: no MVI; M1 (low-risk group): ≤5 MVI in para-cancerous liver tissues; M2 (high-risk group): \>5 MVI, or MVI in distant para-carcinoma liver tissue (Chinese Society of Liver Cancer et al 2015[@CIT0042]).

Surgical Therapies {#S0002-S2005}
------------------

This study followed the established criteria for Couinaud liver segmenting. Surgical methods containing laparotomy and laparoscopic hepatectomy were randomly performed on patients with HCC by experienced surgeons. The indications and type of operation for hepatectomy were usually based on tumor location, remnant liver volume, and the hepatic functional reserve assessed by Child-Turcotte-Pugh classification. Curative hepatectomy was defined as the complete resection of all tumor nodules without involving any major branch of the portal or hepatic veins. Anatomic hepatectomy was characterized as any type of complete excision of at least one segment based on Couinaud's classification in the published literature.[@CIT0053] Nonanatomic hepatectomy referred to wedge resection and tumor enucleation. Clinical "resectional margin distance" was defined as the shortest distance measured from the liver resection margin to the edge of the tumor. An appropriate resection margin length was used if the ideal anatomical resection could not be performed. A negative resection margin was used if the recommended intraoperative resection margin length ≥2 cm was not possible. Postoperative complications within 90 days after surgery were classified as grade I--V based on the Clavien-Dindo classification system.[@CIT0054]

Follow-Up {#S0002-S2006}
---------

All patients were followed up by telephone inquiry or special clinic re-examination. The date of surgery was defined as initiation time. The follow-up was censored on December 31, 2018. The time to recurrence (TTR) was termed the endpoint as the time from date of surgery to the date of first relapse detected on imaging, and was recorded with overall survival (OS) and disease-free survival (DFS). OS was defined as the interval between the date of surgery and the date of patient death, or the date of the last follow-up. DFS was the interval between the date of surgery and the date when tumor recurrence was diagnosed, or the date of the last follow-up, or the date of patient death. Ultrasound and serum AFP levels were postoperatively examined every 3 months within 2 years of diagnosis, and every 6 months after 2 years. Enhanced CT and/or MRI, as well as pathology examination, was performed if the ultrasound showed new liver lesions and/or if serum AFP showed progressive elevation. ER was defined as recurrence time ≤2 years, and LR was defined as \>2 years after curative hepatectomy. The site of recurrence (intra- or extrahepatic) and the size and the number of recurrent nodules were evaluated. Patients with recurrence of HCC were treated with various therapies, including re-hepatectomy, microwave ablation, transcatheter arterial chemoembolization (TACE), immuno-targeted drugs such as sorafenib, radiotherapy, or best supportive care.

Statistical Analysis {#S0002-S2007}
--------------------

SPSS 23.0 (IBM Corporation, Armonk, New York, USA) was used for the analyses, and a *P* value of \<0.05 was considered to be statistically significant. Cox-regression analysis was used to estimate the hazard ratio (HR) with a 95% confidence interval (95% CI) for each of the potential risk factors (*P \<* 0.05 was set as significant). Univariate analysis was applied for risk factors with preliminary estimation. Variable selection methods with three steps (forward, backward, and stepwise; inclusion and exclusion criteria of type I error = 0.1 based on likelihood ratio tests) were adopted in the multivariate analysis. Potential risk factors for predicting ER and LR in univariate analyses that were considered significant (*P* \< 0.05) were selected for the multivariate analysis using the backward stepwise method, with a *P*-value threshold of \<0.05. R (version 3.4.1) with rms software package version 5.1--1 ([<http://www.R-project.org><http://CRAN.R-project.org/package=rms>]{.ul}) was used. Risk factors detected from the multivariate analysis were used to construct nomograms to predict ER and LR, respectively. AUC values (95% CI) of nomograms for both ER and LR were obtained. Using Bootstrap analysis, 75% of all patients were randomly selected 2000 times for internal verification. Harrell's concordance index (C-index) analysis was used to evaluate the consistency probability between predicted cohorts and observed cohorts. The C-index range extended from 0.5 (no discriminant ability) to 1.0 (perfect discriminant ability), and *P* \< 0.05 was considered significant. A calibration curve was plotted to estimate the prognostic performance of the nomograms for ER and LR. The AUC of ROC and C-index analysis was used to compare the predictive power of nomograms with three conventional HCC staging systems/models (the 8th AJCC-TNM staging system, BCLC system, and HKLC system).

Results {#S0003}
=======

Patients {#S0003-S2001}
--------

Total of 318 patients out of 586 recruited HCC patients met the eligibility criteria. Patient characteristics are presented in [Table 1](#T0001){ref-type="table"}. Of the patients excluded, 73 cases had tumor thrombus of the main/branch portal vein, 21 cases had tumor thrombus of the bile duct, three cases had positive surgical margins, 31 cases had incomplete clinical data, five cases died within 90 d of hospitalization, and the follow-up on 135 cases was not available. The median follow-up of eligible patients was 30.1 months (range: 3.2--105.7 months).

Recurrence and Survival {#S0003-S2002}
-----------------------

Total of 164 patients with HCC had postoperative recurrence by the end of the follow-up period. The median time to recurrence (TTR) was 10.6 months (range: 1.0--153.0 months). Out of the 140 patients with ER, 107 cases had intrahepatic recurrence, 24 cases had synchronous intrahepatic recurrence and extrahepatic metastases, including metastases to the pulmonary area (n = 14), peritoneal cavity (n = 6), lymph node (n = 1), bone (n = 1), right adrenal gland (n = 1), and brain (n = 1). Nine patients had extrahepatic metastases only, including metastases to the peritoneal cavity (n = 3), pulmonary (n = 4), lymph node (n = 1), and bone (n = 1). Out of the 24 patients with LR, 21 cases (87.5%, 21/24) had intrahepatic recurrence only, two cases had extrahepatic metastases only, including right adrenal gland + brain (n = 1), chest wall + mediastinal lymph nodes (n = 1), and one case (4.2%, 1/24) had intrahepatic and extrahepatic recurrence with metastases to the pulmonary (n = 1).

Patients with ER received the following therapies: 18 cases received re-resection, 76 cases received TACE, 10 cases received immunotargeted drugs, eight cases received microwave ablation, two cases received radiotherapy, and 26 cases received best supportive care. Patients with LR received the following therapies: eight cases received re-resection, eight cases received TACE, one case received microwave ablation, seven cases received best supportive care. Cumulative recurrence rates of 1, 2, 3, 4, and 5 years were 29.9% (95/318), 44.0% (140/318), 47.8% (152/318), 49.7% (158/318), and 51.6% (164/318), respectively. Disease-free survival (DFS) rates of 1, 2, 3, 4, and 5 years were 66.7% (212/318), 45.9% (146/318), 26.7% (85/318), 12.9% (41/318), and 6.6% (21/318), respectively. Overall survival (OS) rates of 1, 2, 3, 4, and 5 years were 88.7% (282/318), 64.8% (206/318), 36.8% (117/318), 17.6% (56/318), and 9.8% (31/318), respectively.

Risk Factors for Recurrence and Prognostic Nomograms {#S0003-S2003}
----------------------------------------------------

Univariate analysis showed that 25 factors were correlated with ER and three factors were correlated with LR ([Table 1](#T0001){ref-type="table"}). Multivariate analysis showed that patient age, HKLC stage, ALBI, METAVIR fibrosis grade, and MVI were risk factors for ER ([Table 2](#T0002){ref-type="table"}), while the neutrophil to lymphocyte ratio (NLR) and glypican-3 (+) were risk factors for LR ([Table 3](#T0003){ref-type="table"}).Table 2Multivariate Analysis for Postoperative ERFactorsBetaSEP-valueHR95% CIAge (year)**−**0.0360.0160.0230.9640.9340.995HKLC stage I0.0001 IIA0.2770.2770.3171.3190.7672.268 IIB**−**0.1440.4460.7460.8660.3612.074 IIIA0.9850.3830.0102.6791.2635.679 IIIB1.5150.3560.0004.5492.2639.143 IVA1.8351.3580.1776.2680.4379.824ALBI1.2170.5620.0303.3781.12310.164METAVIR fibrosis grade F00.0001 F10.2590.6300.6810.9720.2252.652 F20.1150.7240.8741.1220.2714.638 F31.2040.2820.0003.3331.9175.696 F40.4430.6620.5043.5570.4255.798MVI M00.0111 M10.2690.4650.5631.7650.3081.901 M21.1880.4520.0083.2811.3545.950[^2][^3] Table 3Multivariate Analysis for Postoperative LRFactorsBetaSEP-valueHR95% CIGlypican-3 **+**1 **−−**2.1910.8100.0070.1120.0230.547NLR0.2200.0940.0181.2461.0381.497[^4][^5]

Nomograms for Predicting ER {#S0003-S2004}
---------------------------

The AUC of ROC for the nomogram integrating all independent predictors for ER was 0.860 ([Figure 1A](#F0001){ref-type="fig"}). A prognostic nomogram was established according to the results of the multivariate analysis ([Figure 1B](#F0001){ref-type="fig"}). A score was generated for each risk factor by drawing an upward line to the corresponding scoring axis. The predictive probability of ER was represented by the total score accumulated from each score positioned on the total-score axis.Figure 1(**A**) AUC (0.860) of ROC used to predict ER; (**B**) nomogram used to predict ER. The value of each patient is presented on the axis for each variable in the nomogram. A line was drawn upward to determine the number of points allocated to each variable. (**C**) Internal validation of ER. Using Bootstrap analysis, 75% of all patients were randomly selected 2000 times for internal validation. The AUC of ER in the development set (D-set) was 0.888, while that in the validation set (V-set) was 0.812. (**D**) Calibration curve yielded by C-index analysis \[0.7794 (95% CI, 0.6456--0.9132)\], with strong consistency being obtained between the prediction cohort (x-axis) and the actual observation cohort (y-axis) for the probability of ER. (**E**) ROC curve used to evaluate the ability to predict HCC staging system for postoperative ER.

Internal Validation Results {#S0003-S2005}
---------------------------

Using Bootstrap analysis, 75% of all patients were randomly selected 2000 times for internal validation. The AUC of ROC for ER in the development set (D-set) was 0.888, while that in the validation set (V-set) was 0.812 ([Figure 1C](#F0001){ref-type="fig"}). The calibration plots predicted ER well ([Figure 1D](#F0001){ref-type="fig"}). In our internal validations, the bootstrap-corrected C-index to predict ER in the nomogram was 0.7794 (95% CI, 0.6456--0.9132). The calibration plots showed strong consistency between the prediction cohort and the observation cohort, confirming the repeatability and reliability of this nomogram.

Comparison of the Nomogram to Alternative Staging Models as a Predictor of ER {#S0003-S2006}
-----------------------------------------------------------------------------

The AUC under the ROC of the proposed ER nomogram was 0.860 (95% CI: 0.814--0.935), and was more satisfactory than the AUCs of the three representative conventional HCC staging systems/models; specifically 0.685 (95% CI: 0.625--0.746) for the eighth AJCC-TNM staging system, 0.678 (95% CI: 0.617--0.739) for the HKLC staging system and 0.655 (95% CI: 0.592--0.717) for the BCLC system ([Figure 1E](#F0001){ref-type="fig"}). The C-index of our proposed ER nomogram \[0.7794 (95% CI: 0.6456--0.9132)\] was much higher than those of the three representative conventional HCC staging systems/models; specifically: 0.5913 (95% CI: 0.5481--0.6279) for the eighth AJCC-TNM staging system, 0.5954 (95% CI: 0.5378--0.6184) for the BCLC system, and 0.6226 (95% CI: 0.5623--0.6458) for the HKLC staging system.

Nomograms for Predicting LR and Their Predictive Performance {#S0003-S2007}
------------------------------------------------------------

The AUC under the ROC for the nomogram that integrated all independent predictors for LR was 0.831 ([Figure 2A](#F0002){ref-type="fig"}). A prognostic nomogram was established based on the results of the multivariate analysis ([Figure 2B](#F0002){ref-type="fig"}). A score was generated for each risk factor by drawing an upward line to the corresponding scoring axis. The predictive probability of LR was represented by the total score accumulated from each score positioned on the total-score axis.Figure 2(**A**) AUC (0.831) of ROC curve used to predict LR. (**B**) Nomogram used to predict LR. The value of each patient is presented on the axis for each variable in the nomogram. A line was drawn upward to determine the number of points allocated to each variable. (**C**) Internal validation of LR prediction. Using Bootstrap analysis, 75% of all patients were randomly selected 2000 times for internal validation. The AUC of LR prediction in the development set (D-set) was 0.833, while that in validation set (V-set) was 0.733. (**D**) Calibration curve yielded by C-index analysis \[0.7364 (95% CI, 0.6854--0.7844)\], with strong consistency being obtained between the prediction cohort (x-axis) and the actual observation cohort (y-axis) for the probability of LR. (**E**) ROC curve used to evaluate the ability to predict of HCC staging system for postoperative LR.

Internal Validation Results {#S0003-S2008}
---------------------------

Using Bootstrap analysis, 75% of all patients were randomly selected 2000 times for internal validation. The AUC of the ROC for LR predicted in the D-set was 0.833, while that in the V-set was 0.733 ([Figure 2C](#F0002){ref-type="fig"}). The calibration plots had a strong predictive ability for LR ([Figure 2D](#F0002){ref-type="fig"}). In our internal validation, the bootstrap-corrected C-index to predict LR in the nomogram LR was 0.7364 (95% CI, 0.6854--0.7844). The calibration plots showed strong consistency between the prediction cohort and the observation cohort, validating the repeatability and reliability of this nomogram.

Comparison of the Nomogram to Alternative Clinical Staging Systems as a Predictor of LR {#S0003-S2009}
---------------------------------------------------------------------------------------

The AUC under the ROC of the proposed LR nomogram was 0.831 (95% CI: 0.802--0.903), which was more satisfactory than the three representative conventional HCC staging systems/models; specifically, 0.424 (95% CI: 0.322--0.526) for the eighth AJCC-TNM staging system, 0.422 (95% CI: 0.313--0.532) for the BCLC system, and 0.405 (95% CI: 0.290--0.520) for the HKLC staging system ([Figure 2E](#F0002){ref-type="fig"}). The C-index of our proposed LR nomogram was 0.7364 (95% CI: 0.6854--0.7844), and was much higher than those of the three representative conventional HCC staging systems/models; specifically, 0.4900 (95% CI: 0.4324--0.5956) for the eighth AJCC-TNM staging system, 0.5510 (95% CI: 0.4799--0.6482) for the BCLC system, and 0.5403 (95% CI: 0.4825--0.6156) for the HKLC staging system.

Discussion {#S0004}
==========

This study developed novel nomograms to predict postoperative ER and LR for individual patients with HCC after curative hepatectomy. In China, most HCC patients are treated with curative hepatectomy. These easy-to-use graphical nomograms contain typical clinical variables (preoperative and pathological characteristics) that have the potential to improve the prognostic function of staging systems from the group-level to an individual level. Within this framework, it would be possible to identify patients who are at high risk of recurrence after curative surgery, allowing clinicians to provide appropriate surveillance to detect recurrence as early as possible.

Predictive performance was verified using an internal validation cohort, with a C-index of 0.7794 (95% CI, 0.6456--0.9132) for ER and a C-index of 0.7364 (95% CI, 0.6854--0.7844) for LR. The AUCs of our novel predictive nomograms for ER and LR were 0.860 and 0.831, respectively. These results were more satisfactory than previously reported predictive models/scoring systems ([Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}). Our results confirm previous studies suggesting that ER and LR are separate clinical entities resulting from different risk factors. Specifically, intrahepatic recurrence remains the main cause of ER/LR, with a low proportion of repeat operations. However, it is difficult to distinguish ER and LR based on the clinical or biological characteristics of HCC.[@CIT0055] As a simple alternative, our novel prognostic nomograms for predicting ER and LR after curative hepatectomy, have the advantage in that they: (a) are suitable for all types of patients with HCC after resection, not just one specific group; (b) clearly distinguish ER and LR after operation, and could be used in place of DFS to predict postoperative recurrence; (c) take descriptions of tumor characteristics into account, reasonably select indicators to evaluate basic liver status, and incorporate postoperative pathological indicators.Table 4Nomogram to Predict DFS or Recurrence After Hepatectomy in the Published LiteratureAuthorCountryYearObjectStudy EndpointPVTTBDTTC-Index of ModelLiver Function Reserve IndicatorsLiver CirrhosisCTPMELDALBIClassificationRFMVIRFCho et al[@CIT0012]USA20083-,5yrDFSYesNA0.67YesYesNoY/NNoNANALi et al[@CIT0013]China2014PM3yrNANA0.75NANANAY/NNoY/NYesAng et al[@CIT0014]Singapore20153-,5yrFFRNANA0.69YesNoNoY/NYesNANAShim et al[@CIT0015]Korea2015ER(≤2yr)NoNA0.69YesNANANANAY/NYesShen et al[@CIT0016]China20163-,5yrRFSNANA0.746YesNoNoIshak score (5--6/0--4)NoP/AYesLi et al[@CIT0017]China2016BCLC-0 HCC3-,5yrDFSNoNo0.76YesNoNoY/NNoY/NYesTorzilli et al[@CIT0018]Italy20165yrDFSNANA0.61YesNoNoY/NYesNANAFu et al[@CIT0019]China20161-,3-,5yrRFSNANA0.621YesNoNoNANAY/NYesFeng et al[@CIT0020]China20160.5-,1-,2yrTTRNoNA0.72YesNoNoY/NNoNumber of MVIYesShen et al[@CIT0021]China2017Solitary HCC3-,5yrRFSNANA0.72YesNoNoY/NNoP/AYesFu et al[@CIT0022]China20172-,3yrRFSNoNA0.665NANANAP/AYesP/AYesZhang et al[@CIT0023]China2017Adolescent and young adult HCC1-,3-,5yrDFSNANA0.70YesNoNoY/NNoY/NYesLuo et al[@CIT0024]China20181-,3-,5yrTRRNANA0.630NANANAY/NNoP/AYesGan et al[@CIT0025]China2018AFP(-)HCC1-,3-,5yr RFSYesNA0.661NANANAY/NYesY/NYesGan et al[@CIT0026]China20181-,2-,3yr RFSYesNA0.654YesNoNoNANAY/NYesZheng et al[@CIT0027]China2018Solitary HCC3-,5yr TTRNANA0.639NANANAY/NNoY/NNoChan et al[@CIT0028]Hong Kong, China2018ER(≤2yr)NANA0.713;0.735YesNoYesNANAY/NYesHu et al[@CIT0029]China2018HCC with PVTT0.5yr DFSYesNA0.78YesNANANANANANAChen et al[@CIT0030]China2018EM1-,3yrEMNANA0.73NANANAY/NNoY/NNoKim et al[@CIT0031]Korea20191-,3-,5yr RFSYesYes0.703NoNoNoY/NNoP/ANoWang et al[@CIT0032]China20191-,2-,3yr RFSYesNA0.701YesNoNoY/NNoY/NYesHo et al[@CIT0033]Taiwan,\
China20191-,3-,5yrRFSNANA0.607YesYesYesNANANANALi et al[@CIT0034]China20193-,5yrDFSNANA0.725;0.639NANANAIshak score (0,1--5,6)NoY/NNoZhang et al[@CIT0035]China2019HCC with PVTTER(≤1yr)YesNA0.836YesNANANANANANAZhang et al[@CIT0036]China2019ER(≤1yr)NANANAYesNANANANANANA[^6] Table 5Scoring System to Predict DFS or Recurrence After Hepatectomy in the Published LiteratureAuthorCountryYearAUCLiver Function Reserve IndicatorsLiver CirrhosisObjectStudy EndpointPVTTBDTTCTPMELDALBIClassificationRFMVIRFHung et al[@CIT0038]Hong Kong China20161-,3yr recurrenceNoNA0.675;0.746YesYesNoY/NNoNANAZou et al[@CIT0039]China2017BCLC-A HCC1-,2-,5yr DFSNoNA0.645YesNoNoY/NYesNANATokumitsu et al[@CIT0040]Japan20181-,2yr recurrenceNANA0.78;0.74YesNoNoNANANANA[^7]

A multi-center study in China showed that patient gender, liver fibrosis/cirrhosis, and several, initial stage aggressive tumor characteristics represented risk factors for patients with HCC after hepatectomy.[@CIT0056] However, differences in fibrosis/cirrhosis and microvascular invasion were only described as presence and absence. Some investigators showed that liver fibrosis/cirrhosis is an important risk factor for HCC recurrence after surgery.[@CIT0002] The well-known risk factors for ER in patients with HCC were also confirmed by our multivariate analysis. Evaluation of the prognostic significance of indicators that reflect liver fibrosis/cirrhosis was reasonable for patients with HCC after hepatectomy. However, liver reserve function tends to be overlooked or minimally used by existing staging systems. CTP classification is widely used to assess liver reserve in patients with cirrhosis, and has been incorporated in many HCC staging systems. A model for end-stage liver disease (MELD) score was used to assess the severity of liver dysfunction. Therefore, HCC with chronic liver disease status (fibrosis/cirrhosis) was evaluated in detail using several preoperative non-invasive indicators and the postoperative METAVIR score for assessing the status of non-tumor parts of the liver in our study. This approach was used to clarify how the status of chronic liver disease would impact ER and LR in patients with HCC.

Our study showed that the basic indicators used to evaluate the status of liver disease (such as ALBI and chronic liver disease staging) are risk factors for ER after curative resection. Various non-invasive models have been developed to assess liver fibrosis in patients with HBV or hepatitis C virus (HCV).[@CIT0047],[@CIT0057] For example, APRI and Fib-4 have been recommended as non-invasive indicators under WHO guidelines to diagnose liver fibrosis/cirrhosis in patients with chronic HBV infection.[@CIT0058] However, these indicators were not statistically significant in the univariate analysis of HCC recurrence after hepatectomy in our study. Furthermore, we evaluated how pathological staging and inflammatory activity of chronic liver disease affect HCC recurrence after surgery. We used METAVIR fibrosis grade F0 as reference indicator, with HR only being statistically significant for staging F3 out of F1-4 and staging F0. Unexpectedly, ALBI (B =1.217) had a more significant effect than pathological chronic liver disease staging. ALBI was graded as a simple and objective indicator of evaluating liver function.[@CIT0046] ALBI is also significantly correlated with higher recurrence rates after hepatectomy, and can be used to determine patient prognosis.[@CIT0046],[@CIT0059],[@CIT0060] However, ALBI grade was not statistically significant in the univariate analysis, because patients of the same ALBI grade showed different liver functions in our study. Most HCC patients that underwent hepatectomy in this study were CTP grade A; therefore, the indicator of ALBI that was included in the nomogram to predict ER did not add extra weight in this study.

This study revealed significant heterogeneity in inflammation and fibrosis in different regions of the liver, thus assessing inflammation and fibrosis staging in non-tumor liver areas after hepatectomy might not reflect overall liver status. Previous studies also showed that the severity of liver fibrosis of HCC patients might not be effectively diagnosed by the monitoring models of chronic liver disease without HCC.[@CIT0061] In the current study, chronic liver disease staging F0 was used as reference indicator, with statistical significance in HR only being shown when comparing staging F3 out of F1-4 and staging F0. Thus, the actual risk of liver cirrhosis on postoperative ER requires the development of a monitoring model for HCC patients that have liver cirrhosis. The predictive function of these indicators for HCC recurrence and the need for routinely monitoring fibrosis in the follow-up require further evaluation. Routine liver biopsies might not be needed to monitor postoperative patients with HCC during follow-up, even though such invasive examination serves as a gold standard for assessing liver status.

Various HCC staging systems use different biological characteristics, including tumor diameter/number and vascular invasion, as variables to classify cancer classification. However, these factors are not sufficient to predict the postoperative status of patients after hepatectomy. Thus, we used the most representative systems to describe oncological characteristics, including the 8th AJCC-TNM staging system, BCLC system, and HKLC classification system. These predictive systems primarily use tumor status, tumor size, tumor number, vascular invasion, and serum AFP, failing to provide an accurate assessment of the status of underlying liver disease. Hepatitis B virus (HBV) infection is the main cause of HCC in China.[@CIT0003] The proportion of HCC patients with HBV in the current study represented 85.5% (272/318) of all patients. Furthermore, HCC patients with HBV after postoperative recurrence accounted for 91.25% (146/164) of all patients. HKLC system was established for a large population of HBV-related patients with HCC.[@CIT0051] It was more accurate than the BCLC staging system to predict patient prognosis.[@CIT0062]--[@CIT0064] The AUC of ROC for proposed nomograms was better than the three conventional HCC staging systems/models (the 8th AJCC-TNM staging system, BCLC system, and HKLC system). However, the multivariate analysis showed no difference in HR when comparing the HKLC-IIA/IIB stage with the HKLC-I stage. In comparison, there was a significant difference in HR when comparing the HKLC-IIIA/IIIB stage with the HKLC-I stage. In addition, the negative correlation between tumor size and other adverse critical prognostic factors (such as vascular invasion, poorly differentiated tumors, and multiple lesions) was reported in a large cohort study.[@CIT0065] The importance of tumor size as a prognostic factor for HCC is highly controversial,[@CIT0065],[@CIT0066] affirming that postoperative ER after hepatectomy cannot be solely predicted on tumor characteristics for HCC.

As an important component of the AJCC-TNM system, microvascular invasion (MVI) is considered to represent a histological indicator of HCC recurrence and long-term survival after hepatectomy.[@CIT0067],[@CIT0068] However, MVI is overlooked by existing staging systems. As shown in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}, in current predictive models or scoring systems of HCC recurrence after hepatectomy, MVI is simply classified as present or absent.[@CIT0013],[@CIT0016],[@CIT0017],[@CIT0019],[@CIT0021]--[@CIT0028],[@CIT0030],[@CIT0032],[@CIT0034] Some studies do not even evaluate MVI.[@CIT0012],[@CIT0014],[@CIT0015],[@CIT0018],[@CIT0029],[@CIT0031],[@CIT0033],[@CIT0036],[@CIT0039] Considering the potential role of MVI in predicting the recurrence of HCC in patients following hepatectomy, MVI absence (M0) was used as a reference indicator in our study. Of note, strong significance was obtained for HR when comparing MVI M2 and MVI M0. In addition, small HCC (≤3 cm) may be detected with MVI, and multinodular HCC with ≤3 nodules might arise from MVI, leading to the formation of satellite nodules. Consequently, the biological behavior of actual tumors was not pragmatically reflected by the early-stage in these patients.[@CIT0068] Therefore, future studies are needed to verify the role of MVI in predicting HCC recurrence in patients following hepatectomy.

Our study showed that LR might be associated with inflammation and glypican-3 positive expression. A previous study showed that inflammation contributes to the development and prognosis of HCC.[@CIT0069] Neutrophils produce chemokines and cytokines, which promote the proliferation, angiogenesis, invasion, and metastasis of tumors. On the other hand, lymphocytes produce cytotoxic factors that enhance antitumor immune responses.[@CIT0070] Increased platelet/lymphocyte ratio (PLR) is associated with a higher recurrence rate and poorer prognosis of patients with HCC after hepatectomy.[@CIT0069] Our results supported that neutrophil/lymphocyte ratio (NLR) could be used as an independent prognostic factor for HCC after hepatectomy.[@CIT0071] However, some studies showed that NLR is not associated with HCC recurrence and DFS after surgery.[@CIT0072],[@CIT0073] These differences might be attributed to the fact that current studies on prognosis of liver cancer patients lack supporting data on neutrophil and lymphocyte subgroups. These groups might maintain the balance between tumor-promoting and antitumor actions, along with their relationship with the platelet and tumor microenvironment. Thus, this group should be selected as clinical therapeutic targets to improve patient prognosis in future research.

The overexpression of GPC3 is significantly correlated with highly invasive activity of tumor cells.[@CIT0074],[@CIT0075] GPC3 is significantly correlated with poor prognosis of patients with HCC.[@CIT0074],[@CIT0075] Furthermore, GPC3 can be detected in the blood samples of HCC patients.[@CIT0075] GPC3 is valuable for monitoring overall survival rates (OS) and disease-free survival (DFS) for patients with HCC. Our internal validation analysis showed that the AUC of the ROC curve in the internal validation cohort was 0.812 for D-set and 0.733 for V-set), respectively. The values of AUC and even the predictive power of nomograms could be improved if more large-scale multicenter studies that incorporate GPC3 and inflammation factors could be performed in the future.

Predictive systems/models must be able to detect the risk factors of ER and LR accurately. Moreover, these systems need to be simple and based on easily available clinical data. The novel nomograms proposed in our study meet these baseline requirements, providing the opportunity to gain a prognostic evaluation for ER and LR after curative hepatectomy. The current study has limitations such as the lack of large-scale prospective data, and the loss of follow-up on some patients. Therefore, the proposed nomograms require external validation in more multicenter prospective samples. In addition, our prognostic nomogram might not be applicable to HCC patients with HCV-infection, because most of our patients had HBV-infection.

In conclusion, risk factors of ER and LR for patients with HCC after curative hepatectomy can be predicted by the novel prognostic nomograms. Our novel monitoring models are of clinical use for individualized follow-up and therapeutic strategies, and could potentially improve prognosis and prolong survival of patients with HCC.
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[^1]: **Abbreviations:** ER, early recurrence; LR, late recurrence; HR, hazard ratio; CI, confidence interval; dis-course, disease course; DM, diabetes mellitus; HV, hepatitis virus; MD, maximum diameter; PH, portal hypertension; SR, spontaneous rupture; BS, blood sugar; ALT, glutamic pyruvic transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; APRI, aspartate aminotransferase-to platelet ratio; PA, prealbumin; γ-GGT, γ-glutamyl transpeptidase; 5ʹ-NT, 5ʹ-nucleotidase; TBA, total bile acid; GPR, Gamma-glutamyl transpeptidase (GGT)-to platelet ratio; TP, total protein; ALB, albumin; GLB, globulin; ALBI, albumin-bilirubin; AG, albumin/globulin ratio; TBIL, total bilirubin; DBIL, direct bilirubin; WBC, white blood cell; NLR, neutrophil/lymphocyte ratio; MONO, monocyte; MLR, monocyte/lymphocyte ratio; Hb, hemoglobin; PLR, platelet/lymphocyte ratio; AFP, alpha-fetoprotein; CC, complication classification; AT, adjuvant therapy; HR, hazard ratio.

[^2]: **Note:** Beta: standardized coefficient.

[^3]: **Abbreviations:** SE, standard error; HR, hazard ratio; CI, confidence interval; HKLC, Hong Kong Liver Cancer; ALBI, albumin-bilirubin; MVI, microvascular invasion.

[^4]: **Note:** Beta: standardized coefficient.

[^5]: **Abbreviations:** SE, standard error; HR, hazard ratio; CI, confidence interval.

[^6]: **Abbreviations:** PVTT, portal vein tumor thrombosis; BDTT, bile duct tumor thrombosis; CTP, child-turcotte-pugh; MELD, model for end-stage liver disease; ALBI, albumin-bilirubin; RF, risk factor; MVI, microvascular invasion; DFS, disease-free survival; NA, not available; Y/N, Yes/No; PM, pulmonary metastases; FFR, freedom from recurrence; ER, early recurrence; RFS, relapse-free survival; P/A, presence versus absence; TTR, time to recurrence; TRR, tumor recurrence rate; EM, extrahepatic metastases.

[^7]: **Abbreviations:** DFS, disease-free survival; PVTT, portal vein tumor thrombosis; BDTT, bile duct tumor thrombosis; AUC, area under curve; CTP, child-turcotte-pugh; MELD, model for end-stage liver disease; ALBI, albumin-bilirubin; RF, risk factor; MVI, microvascular invasion; DFS, disease-free survival; Y/N, Yes/No, NA, not available.
